Avenue Therapeutics, Inc.
ATXI
$0.252
$0.00190.76%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 24.37% | -43.30% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -49.43% | 11.80% | |||
| Operating Income | 49.43% | -11.80% | |||
| Income Before Tax | 49.50% | -14.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 49.50% | -14.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 36.36% | 22.22% | |||
| Net Income | 49.80% | -14.26% | |||
| EBIT | 49.43% | -11.80% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 299.43% | 70.10% | |||
| Normalized Basic EPS | 57.77% | 20.20% | |||
| EPS Diluted | 299.43% | 70.10% | |||
| Normalized Diluted EPS | 57.77% | 20.20% | |||
| Average Basic Shares Outstanding | 18.44% | 43.16% | |||
| Average Diluted Shares Outstanding | 18.44% | 43.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||